<p>There's a question every LP should ask before writing a check: <strong>"Did you build this, or did you buy it?"</strong></p>

<p>At Veracor Capital, the answer is unambiguous. We built it. Every company in our portfolio — KureCare, EliteMD, Pure Pak, the Kure Health platform — was created, operated, and scaled by our team before we ever formed a fund.</p>

<h2>The Fund Didn't Come First. The Work Did.</h2>

<p>In 2005, Kenton Gray wasn't raising capital. He was in the clinic. He was developing what would become Signal-Based Medicine — a methodology that treats the root cause of chronic disease rather than managing symptoms. Over the next 15 years, that methodology would be tested on more than 47,000 patients with a 95% clinical success rate.</p>

<p>That's not a pitch deck number. That's a clinical track record built patient by patient, year after year.</p>

<p>By the time Veracor Capital was formally established in 2022, the portfolio companies already existed. KureCare was generating revenue. EliteMD had a national network. Pure Pak was manufacturing at scale in a 150,000 sq ft FDA-registered facility. The fund wasn't created to find deals — it was created to provide growth capital to companies with proven operations.</p>

<h2>2025: The Intentional Build Year</h2>

<p>We're transparent about where we are. 2025 was a build year — by design, not by accident.</p>

<p>KureCare, operating as a division of Max Health LA, generated <strong>$4.6 million in revenue</strong> in 2025. That's not venture-scale yet, but it's real revenue from real patients with real outcomes. It's the foundation.</p>

<p>RIIZE STRIPS had a strong first year in 2024, generating <strong>$3.6 million in revenue</strong> as a prescription-only product. But the team made a strategic decision: pivot to direct-to-consumer. That meant 2025 was a retooling year — rebuilding the go-to-market strategy, reformulating for DTC distribution, and preparing for a nationwide launch in 2026.</p>

<p>KureOS, our AI-powered clinical decision support platform, entered development. The Women's Empowerment Fund was structured. The multi-fund strategy was architected.</p>

<p>Build years aren't glamorous. But they're necessary. And every operator knows the difference between a company that skips this phase and one that gets it right.</p>

<h2>The People Aren't New — Even If the Fund Is</h2>

<p>Veracor Capital is a young fund. We own that. But the people behind it have two decades of operational healthcare experience. Kenton Gray didn't come from Wall Street — he came from the clinic, the manufacturing floor, and the operating room of building healthcare companies from zero.</p>

<p>He's a U.S. Army veteran who built a career in healthcare innovation, not financial engineering. The fund exists because the companies needed growth capital, and the team believed institutional investors deserve access to a portfolio with real operational proof — not just a thesis and a term sheet.</p>

<h2>What This Means for Investors</h2>

<p>The risk profile of Veracor Capital is fundamentally different from a typical emerging manager:</p>

<ul> <li><strong>Revenue-generating assets today</strong> — not pre-revenue promises</li> <li><strong>20 years of clinical validation</strong> — not untested science</li> <li><strong>Vertically integrated supply chain</strong> — from formulation to manufacturing to distribution</li> <li><strong>Founder-operator alignment</strong> — the GP built the portfolio before raising LP capital</li> </ul>

<p>We're not asking investors to bet on an idea. We're asking them to back an ecosystem that already works — and help us scale it.</p>

<h2>2026: The Launch Year</h2>

<p>Everything we built in 2025 ships in 2026. RIIZE goes DTC nationwide. KureOS enters clinical pilots. The Reg CF filing opens retail investor access. The multi-fund strategy goes live.</p>

<p>The foundation is laid. The companies are real. The patients are healed. Now it scales.</p>